|Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies|
J Naidoo, DB Page, BT Li, LC Connell, K Schindler, ME Lacouture, ...
Annals of Oncology 26 (12), 2375-2391, 2015
|Neoadjuvant PD-1 blockade in resectable lung cancer|
PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ...
New England Journal of Medicine 378 (21), 1976-1986, 2018
|Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study|
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet 395 (10241), 1907-1918, 2020
|Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy|
J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ...
Journal of Clinical Oncology 35 (7), 709, 2017
|Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer|
V Anagnostou, KN Smith, PM Forde, N Niknafs, R Bhattacharya, J White, ...
Cancer discovery 7 (3), 264-276, 2017
|Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab|
LC Cappelli, AK Gutierrez, AN Baer, J Albayda, RL Manno, U Haque, ...
Annals of the rheumatic diseases 76 (1), 43-50, 2017
|Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma–like and non–small cell carcinoma–like subsets|
N Rekhtman, MC Pietanza, MD Hellmann, J Naidoo, A Arora, H Won, ...
Clinical Cancer Research 22 (14), 3618-3629, 2016
|Genome-wide cell-free DNA fragmentation in patients with cancer|
S Cristiano, A Leal, J Phallen, J Fiksel, V Adleff, DC Bruhm, SŲ Jensen, ...
Nature 570 (7761), 385-389, 2019
|Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology|
JA Thompson, BJ Schneider, J Brahmer, S Andrews, P Armand, S Bhatia, ...
Journal of the National Comprehensive Cancer Network 17 (3), 255-289, 2019
|Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1|
J Naidoo, K Schindler, C Querfeld, K Busam, J Cunningham, DB Page, ...
Cancer immunology research 4 (5), 383-389, 2016
|Immune modulation for cancer therapy|
J Naidoo, DB Page, JD Wolchok
British journal of cancer 111 (12), 2214-2219, 2014
|Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma|
L Chen, J Douglass, L Kleinberg, X Ye, AE Marciscano, PM Forde, ...
International Journal of Radiation Oncology* Biology* Physics 100 (4), 916-925, 2018
|Pneumonitis in non–small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors|
K Suresh, KR Voong, B Shankar, PM Forde, DS Ettinger, KA Marrone, ...
Journal of Thoracic Oncology 13 (12), 1930-1939, 2018
|Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab|
J Yuan, J Zhou, Z Dong, S Tandon, D Kuk, KS Panageas, P Wong, X Wu, ...
Cancer immunology research 2 (2), 127-132, 2014
|Cardiovascular toxicities associated with immune checkpoint inhibitors|
JR Hu, R Florido, EJ Lipson, J Naidoo, R Ardehali, CG Tocchetti, AR Lyon, ...
Cardiovascular research 115 (5), 854-868, 2019
|Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib|
J Naidoo, CS Sima, K Rodriguez, N Busby, K Nafa, M Ladanyi, GJ Riely, ...
Cancer 121 (18), 3212-3220, 2015
|Large cell neuroendocrine carcinoma of the lung: clinico-pathologic features, treatment, and outcomes|
J Naidoo, ML Santos-Zabala, T Iyriboz, KM Woo, CS Sima, JJ Fiore, ...
Clinical lung cancer 17 (5), e121-e129, 2016
|Dynamics of tumor and immune responses during immune checkpoint blockade in non–small cell lung cancer|
V Anagnostou, PM Forde, JR White, N Niknafs, C Hruban, J Naidoo, ...
Cancer research 79 (6), 1214-1225, 2019
|Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities|
K Suresh, J Naidoo, CT Lin, S Danoff
Chest 154 (6), 1416-1423, 2018
|Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen|
LC Cappelli, JR Brahmer, PM Forde, DT Le, EJ Lipson, J Naidoo, L Zheng, ...
Seminars in arthritis and rheumatism 48 (3), 553-557, 2018